Table 2.
Established diagnostic biomarkers in the cerebrospinal fluid CSF of Alzheimer’s disease (AD) a [20] and showed 85% sensitivity cutoff values for AD dementia diagnosis [21].
| Biomarkers | Controls (pg/mL) | AD (pg/mL) | % Sensitivity (AD-Control) | % Sensitivity (MCI-Control) |
|---|---|---|---|---|
| Aβ42 | 794 ± 20 | <500 * | 73 (≥75 years) | 60 (≥75 years) |
| tau peptide | 136 ± 89 (21–50 years) | b | 74 (≤64 years) | 65 (≤64 years) |
| 243 ± 127 (51–70 years) | >450 | 53 (65–74 years) | 49 (65–74 years) | |
| 341 ± 171 (>71 years) | >600 * | 61 (≥75 years) | 46 (≥75 years) | |
| p-tau-181 | 23 ± 2 | >60 | 37 (≥75 years) | 30 (≥75 years) |
a Data obtained using innogenetics single 96-well ELISA kits. b This is not relevant for sporadic AD, because it is only for patients >60 years of age. * p < 0.001.